Homart Pharmaceuticals Pty Ltd v Careline Australia Pty Ltd [2017] FCA 403

Homart Pharmaceuticals Pty Ltd v Careline Australia Pty Ltd [2017] FCA 403

Homart Pharmaceuticals intentionally adopted features of Careline's CHANTELLE bio-placenta product get-up, leading to conduct that is misleading or deceptive or likely to mislead or deceive consumers under s 18 of the ACL. The distinctive combination of features, not dispelled by differences in branding (CHÉRI Australia vs CHANTELLE Sydney), justifies relief. Careline's cross-claim succeeds; Homart's claim fails as alleged representations on WeChat and in legal letters were not, in context, actionable under s 18.

Jurisdiction
Australia
Judgment Date
20 April 2017
Procedural Posture
Civil / Final Liability Judgment; Quantum Separated
Outcome
Careline cross-claim succeeds; Homart's claim dismissed
Legal Topics
['misleading or Deceptive Conduct' 'product Get Up' 'passing Off' 'consumer Protection']
['trade Practices' 'commercial Law'] ['misleading or Deceptive Conduct' 'product Get Up' 'passing Off' 'consumer Protection']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Procedural Posture

Civil / Final Liability Judgment; Quantum Separated

Legal Issues

  1. 1 ['Whether similarities in product get-up constitute misleading or deceptive conduct under s 18 of the ACL' 'Whether representations on WeChat and in legal letters are actionable under ACL s 18']

Ratio Decidendi

Homart Pharmaceuticals intentionally adopted features of Careline's CHANTELLE bio-placenta product get-up, leading to conduct that is misleading or deceptive or likely to mislead or deceive consumers under s 18 of the ACL. The distinctive combination of features, not dispelled by differences in branding (CHÉRI Australia vs CHANTELLE Sydney), justifies relief. Careline's cross-claim succeeds; Homart's claim fails as alleged representations on WeChat and in legal letters were not, in context, actionable under s 18.

Court Disposition

Careline cross-claim succeeds; Homart's claim dismissed

Orders

  • ['Declaration that Homart engaged in misleading or deceptive conduct by offering for sale bio-placenta skin product in current packaging.' "Injunction restraining Homart from selling, offering for sale, distributing, promoting, and/or marketing bio-placenta oil skin care product in packaging depicted or deceptively...